Figure 11 displays a forest plot for the network meta-analysis of studies reporting ACR50 response rates. Two comparisons were used in this analysis. Study-level data used in this Figure are presented in Appendix C. This figure is described further in the KQ1 Results section “Non-TNF Biologic Plus MTX Versus Either Non-TNF Biologic or MTX”. For the combination of ABA plus MTX versus MTX monotherapy, the figure’s results were described as follows: “The NWMA found significant differences in ACR50 response when comparing ABA plus MTX with MTX monotherapy (RR, 1.34; 95% CI, 1.16 to 1.54), consistent with the results from the AGREE and AVERT trials”. For the combination of TCZ plus MTX versus MTX monotherapy, the figure’s results were described as follows: “In the NWMA, TCZ plus MTX showed higher ACR50 response rates and less radiographic progression than MTX monotherapy (RR, 1.29; 95% CI, 1.13 to 1.47 and SMD −0.26; 95% CI, −0.40 to −0.12, respectively)”.

Figure 11Forest plot for network meta-analysis of ACR50 response rates: Non-TNF biologic plus MTX versus MTX

95% CI = 95% confidence interval; ACR50 = American College of Rheumatology 50% improvement; MTX = methotrexate; RR = relative risk; TNF = tumor necrosis factor; vs. = versus.

From: Results

Cover of Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update
Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 211.
Donahue KE, Gartlehner G, Schulman ER, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.